alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Amendment to Amended and Restated Unisys Directors Stock Option Plan



 Exhibit 10.5 
 Amendment to 
 Unisys Directors Stock Option Plan 
 Effective February 12, 2009 
 The Unisys Directors Stock Option Plan (the “Plan”) is hereby amended,
effective February 12, 2009, as follows: 
 1. Section 7.9(a) of the Plan, entitled “Adjustments to Reflect Capital Changes”, is amended
to read in its entirety as follows: 
 7.9 Adjustments to Reflect Capital Changes. 
 (a) Recapitalization. The number and kind of shares subject to outstanding Awards, the Purchase Price or Exercise Price for such
shares, and the number and kind of shares available for Awards subsequently granted under the Plan shall be proportionately adjusted to reflect any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other change
in capitalization with a similar substantive effect upon the Plan or the Awards granted under the Plan, consistent with the treatment of shares of Company Common Stock not subject to the Plan, and such that (1) on an aggregate basis, the excess
of the Fair Market Value of the shares of Company Common Stock subject to outstanding Options over the Purchase Price for such shares (the “Spread”) immediately after the change does not exceed the Spread immediately before the change,
(2) on a share by share basis, the ratio of the Fair Market Value of the shares of Company Common Stock subject to such Options to the Purchase Price for such shares is not more favorable to the Participant immediately after the change as
compared to such ratio immediately before the change, (3) to the extent new Options are granted, any old, related Options shall be cancelled, (4) all other terms of the Options remain the same except to the extent they become inoperative
by reason of the transaction, and (5) no additional benefits are provided under any new or adjusted Options. 
 2. Except as amended hereby, the Plan
shall continue in full force and effect.
EXHIBIT 10.3 (e)
 FIRST AMENDMENT TO  LOAN AGREEMENT
 Amendment Borrower Lender
 Loan Agreement
 Line of Credit Note Guidance Line of Credit
  Loan Documents
   Definitions
   Amendments
  Advances




---



##### 



Guidance Line of Credit provided however
  Letters of Credit. Letters of Credit provided Application Letter of Credit Liabilities
 FIRST AMENDMENT TO LOAN AGREEMENT
    
    Page 2




---



##### 



Representations, Warranties, Ratification and Reaffirmation
  FIRST AMENDMENT TO LOAN AGREEMENT
    
    Page 3




---



##### 



Miscellaneous
     THIS WRITTEN AGREEMENT REPRESENTS THE FINAL AGREEMENT AMONG THE PARTIES RELATING TO THE SUBJECT
MATTER HEREOF AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL
AGREEMENTS OF THE PARTIES.
 THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES.
 FIRST AMENDMENT TO LOAN AGREEMENT
    
    Page 4




---



##### 



BORROWER:


INTERPHASE CORPORATION,
a Texas corporationBy:
    /s/ Thomas N. Tipton, Jr.Thomas N. Tipton, Jr.Chief Financial OfficerLENDER:
TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, a national banking
associationBy:
    /s/ Richard L. RogersRichard L. RogersSenior Vice President FIRST AMENDMENT TO LOAN AGREEMENT
    
    Page 5
<PAGE>
                                                                    EXHIBIT 10.4

                        [OSI PHARMACEUTICALS LETTERHEAD]

                          ADDENDUM TO EMPLOYMENT OFFER
                                FOR BARBARA WOOD

                           CHANGE OF CONTROL AGREEMENT

This Agreement dated, October 4, 2001, between OSI Pharmaceuticals and Barbara
Wood:

In the event OSI is sold or merged with another Company resulting in a change of
control (CHANGE OF CONTROL), and your employment with the Controlling Company is
terminated (including if you voluntarily terminate your employment for "Good
reason"*) at any time within six (6) months following a CHANGE OF CONTROL
transaction, unless such termination is for "cause", death, disability or you
voluntarily leave without "Good Reason", you will be entitled to receive the
benefits described below.

      1. In lieu of any further salary and bonus payments to you for periods
subsequent to the date of termination, the Controlling Company shall pay you the
following benefits:

            (a) A lump sum severance payment equal to your annual salary for a
period of twelve (12) months; and,

            (b) All unpaid, accrued vacation through the date of termination.

      2. After the termination, the Controlling Company shall arrange to provide
you and your dependents, as may be the case, with health benefits substantially
similar to those which you and your dependents were receiving immediately prior
to the sale or Change of Control and up to one (1) years after the sale or
Change of Control.

*Good Reason for termination of employment includes (i) a decrease in your total
compensation package, (ii) the assignment of duties or responsibilities which
are not commensurate with your position immediately prior to the sale or Change
of Control, or (iii) you are required to relocate to an office or facility more
than forty (40) miles from your present location or forty (40) miles from your
home.

OSI Pharmaceuticals, Inc.

By:  /s/ COLIN GODDARD                       /s/ BARBARA WOOD
     -------------------------------         -----------------------------------
         Colin Goddard                       Barbara Wood
         CEO and Chairman
[Federal Register Volume 74, Number 22 (Wednesday, February 4, 2009)]
[Notices]
[Pages 6042-6043]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-2273]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Environmental Health Sciences; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material,

[[Page 6043]]

and personal information concerning individuals associated with the 
grant applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Environmental Health 
Sciences Special Emphasis Panel; Pathways to Independence/Career 
Development.
    Date: February 25, 2009.
    Time: 1 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: NIEHS/National Institutes of Health, Building 4401, East 
Campus, 79 T.W. Alexander Drive, Research Triangle Park, NC 27709, 
(Telephone Conference Call).
    Contact Person: Janice B. Allen, PhD, Scientific Review 
Administrator, Scientific Review Branch, Division of Extramural 
Research and Training, Nat. Institute of Environmental Health 
Science, P.O. Box 12233, MD EC-30/Room 3170 B, Research Triangle 
Park, NC 27709, (919) 541-7556.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, 
Biometry and Risk Estimation--Health Risks from Environmental 
Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety 
Training; 93.143, NIEHS Superfund Hazardous Substances--Basic 
Research and Education; 93.894, Resources and Manpower Development 
in the Environmental Health Sciences; 93.113, Biological Response to 
Environmental Health Hazards; 93.114, Applied Toxicological Research 
and Testing, National Institutes of Health, HHS)

    Dated: January 27, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-2273 Filed 2-3-09; 8:45 am]
BILLING CODE 4140-01-P
§ 93.501 Opportunity to contest findings of research misconduct and administrative actions. ( a ) *Opportunity to contest.* A respondent may contest ORI findings of research misconduct and HHS administrative actions, including any debarment or suspension action, by requesting a hearing within 30 days of receipt of the charge letter or other written notice provided under § 93.405.
( b ) *Form of a request for hearing.* The respondent's request for a hearing must be— ( 1 ) In writing;
( 2 ) Signed by the respondent or by the respondent's attorney; and
( 3 ) Sent by certified mail, or other equivalent (*i.e.*, with a verified method of delivery), to the DAB Chair and ORI.
( c ) *Contents of a request for hearing.* The request for a hearing must— ( 1 ) Admit or deny each finding of research misconduct and each factual assertion made in support of the finding;
( 2 ) Accept or challenge each proposed HHS administrative action;
( 3 ) Provide detailed, substantive reasons for each denial or challenge;
( 4 ) Identify any legal issues or defenses that the respondent intends to raise during the proceeding; and
( 5 ) Identify any mitigating factors that the respondent intends to prove.
( d ) *Extension for good cause to supplement the hearing request.* ( 1 ) After receiving notification of the appointment of the ALJ, the respondent has 10 days to submit a written request to the ALJ for supplementation of the hearing request to comply fully with the requirements of paragraph (c) of this section. The written request must show good cause in accordance with paragraph (d)(2) of this section and set forth the proposed supplementation of the hearing request. The ALJ may permit the proposed supplementation of the hearing request in whole or in part upon a finding of good cause.
( 2 ) Good cause means circumstances beyond the control of the respondent or respondent's representative and not attributable to neglect or administrative inadequacy.
§ 82.33 How will NIOSH inform the public of changes to the scientific elements underlying the dose reconstruction process? ( a ) NIOSH will publish a notice in the Federal Register informing the public of changes and the rationale for the changes. This notice will also provide a summary of the recommendations and comments received from the Advisory Board and the public, as well as responses to the comments.
( b ) NIOSH may take into account other factors and employ other procedures than those specified in this subpart, if circumstances arise that require NIOSH to implement a change more immediately than the procedures in this subpart allow.
Amendment to Management Pension Plan effective January 1, 2008



 Exhibit (10)(iii)(A)(17.16) 
 AMENDMENT TO 
 CINCINNATI BELL MANAGEMENT PENSION PLAN 
 The Cincinnati Bell Management Pension Plan (the “Plan”) is hereby amended, effective as of January 1, 2008 and in order to limit to no
more than $15,000 the amount of a certain ancillary death benefit provided under the Plan, by adding a Subsection 9.3.3 to the Plan reading as follows immediately after Plan Subsection 9.3.2. 
 9.3.3 Notwithstanding any other provision of the Plan (or the Prior Death Benefit Plan), the amount of any death benefit that becomes
payable under the foregoing subsections of this Section 9.3 (and under the Prior Death Benefit Plan) with respect to any person who (a) is or was a participant in the Plan, (b) did not have his employment with the Affiliated Employers
end prior to July 1, 1989, and (c) dies on or after January 1, 2008 shall not in any event exceed $15,000 (or, if less, the amount of such death benefit that would apply in the absence of the provisions of this Subsection 9.3.3).

 IN ORDER TO EFFECT THE FOREGOING PLAN CHANGE, the Plan’s sponsor, Cincinnati Bell Inc., has caused its name to be subscribed to this
Plan amendment. 
  

			
	CINCINNATI BELL INC.
		
	By:	 	/s/ Christopher J. Wilson
	Title:	 	V.P. General Counsel & Secretary
	Date:
#### § 63a.5 How to apply for a training grant.

Any agency, institution, or entity interested in applying for a grant under this part must submit an application at the time and in the form and manner that the Secretary may require.
###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 1 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 4 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 5 is placed in the separate grouping of parts pertaining to patents regulations.

#### § 11.801 Registration, recognition and disciplinary matters.

An applicant for registration or recognition to practice before the Office, or a practitioner in connection with an application for registration or recognition, or a practitioner in connection with a disciplinary or reinstatement matter, shall not:

(a) Knowingly make a false statement of material fact; or

(b) Fail to disclose a fact necessary to correct a misapprehension known by the person to have arisen in the matter, fail to cooperate with the Office of Enrollment and Discipline in an investigation of any matter before it, or knowingly fail to respond to a lawful demand or request for information from an admissions or disciplinary authority, except that the provisions of this section do not require disclosure of information otherwise protected by § 11.106.
###### Editorial Note on Part 1

#### Editorial Notes:

1. In Patent and Trademark Office publications and usage the part number is omitted from the numbers of §§ 1.1 to 1.352 and the numbers to the right of the decimal point correspond with the respective rule numbers.

2. For nomenclature changes to part 1, see 68 FR 14335, Mar. 25, 2003; 87 FR 68904, Nov. 17, 2022.

#### § 1.134 Time period for reply to an Office action.

An Office action will notify the applicant of any non-statutory or shortened statutory time period set for reply to an Office action. Unless the applicant is notified in writing that a reply is required in less than six months, a maximum period of six months is allowed.

[62 FR 53194, Oct. 10, 1997]

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 1 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 4 is placed in the separate grouping of parts pertaining to patents regulations.

###### Editorial Note on Subchapter A of Chapter I

#### Editorial Note:

Part 5 is placed in the separate grouping of parts pertaining to patents regulations.
# **EXHIBIT 32.1**

| **CERTIFICATION** |
|-------------------|

*Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

In connection with the Quarterly Report of Advanced Cellular Technology, Inc. (the “Company”) on Form 10-QSB for the period ended December 31, 2002 as filed with the Securities and Exchange Commission on the datehereof (the “Report), Dean Antonis, as Principal Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

| (1)    | the Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934; and                                         |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|                       |                                                                                                                             |
| (2)    | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |

/s/ Dean Antonis                       Dean AntonisPresident and Principal Executive OfficerDate:  September 5, 2003This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 1 is placed in the separate grouping of parts pertaining to patents regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 4 is placed in the separate grouping of parts pertaining to patents regulations.

Editorial Note on Subchapter A of Chapter I
Editorial Note: Part 5 is placed in the separate grouping of parts pertaining to patents regulations.

§ 11.303 Candor toward the tribunal. ( a ) A practitioner shall not knowingly: ( 1 ) Make a false statement of fact or law to a tribunal or fail to correct a false statement of material fact or law previously made to the tribunal by the practitioner;
( 2 ) Fail to disclose to the tribunal legal authority in the controlling jurisdiction known to the practitioner to be directly adverse to the position of the client and not disclosed by opposing counsel in an *inter partes* proceeding, or fail to disclose such authority in an *ex parte* proceeding before the Office if such authority is not otherwise disclosed; or
( 3 ) Offer evidence that the practitioner knows to be false. If a practitioner, the practitioner's client, or a witness called by the practitioner, has offered material evidence and the practitioner comes to know of its falsity, the practitioner shall take reasonable remedial measures, including, if necessary, disclosure to the tribunal. A practitioner may refuse to offer evidence that the practitioner reasonably believes is false.
( b ) A practitioner who represents a client in a proceeding before a tribunal and who knows that a person intends to engage, is engaging or has engaged in criminal or fraudulent conduct related to the proceeding shall take reasonable remedial measures, including, if necessary, disclosure to the tribunal.
( c ) The duties stated in paragraphs (a) and (b) of this section continue to the conclusion of the proceeding, and apply even if compliance requires disclosure of information otherwise protected by § 11.106.
( d ) In an *ex parte* proceeding, a practitioner shall inform the tribunal of all material facts known to the practitioner that will enable the tribunal to make an informed decision, whether or not the facts are adverse.
( e ) In a proceeding before the Office, a practitioner shall disclose to the Office information necessary to comply with applicable duty of disclosure provisions.
**Exhibit 32
**Certification Pursuant to Rule 13a-14(b) or 15d-14(b) ofthe Securities Exchange Act of 1934 and		Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code as adopted pursuant to Section 906		of the Sarbanes-Oxley Act of 2002**

The certification set forth below is being submitted in connection with theQuarterly Report on Form 10-Q for the period ended September 30, 2011 (the “Report”)for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of theSecurities Exchange Act of 1934 and Section 1350 of Chapter 63 ofTitle 18 of the United States Code 

Kenneth J. Zagzebski, President and Chief Executive Officer and Kelly M. Huntington,Senior Vice President and Chief Financial Officer of IPALCO Enterprises, Inc.(“IPALCO”), each certifies that, to the best of his or her knowledge: 
- The Report fully complies with the requirements of Section 13(a) or	15(d) of the Secruties Exchange Act of 1934; and 
- The information contained in the Report fairly presents, in all material	respects, the financial condition and results of operations of IPALCO. 
 /s/ Kenneth J. Zagzebski  /s/ Kelly M. Huntington  Kenneth J. Zagzebski  Kelly M. Huntington  *President and Chief Executive Officer* *Vice President and Chief Financial Officer*  November 3, 2011 November 3, 2011       
A signed original of this written statement required by Section 906 has beenprovided to IPALCO and will be retained by IPALCO and furnished to theSecurities and Exchange Commission or its staff upon request.**
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2170 Introduced in House (IH)]

110th CONGRESS
  1st Session
                                H. R. 2170

 To prevent any individual who has been convicted of a sexual offense 
involving a minor from serving in the Department of the Interior or the 
                       Department of Agriculture.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 3, 2007

 Mr. Pearce (for himself and Mr. Radanovich) introduced the following 
 bill; which was referred to the Committee on Oversight and Government 
                                 Reform

_______________________________________________________________________

                                 A BILL

 
 To prevent any individual who has been convicted of a sexual offense 
involving a minor from serving in the Department of the Interior or the 
                       Department of Agriculture.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Preventing the Endangerment of 
Children on Recreational Lands by Sexual Violators Act''.

SEC. 2. RESTRICTION.

    (a) In General.--An individual convicted by a Federal, State, or 
local court of competent jurisdiction of a sexual offense involving a 
minor shall not, after the date as of which that conviction becomes or 
became final, be eligible to serve in the Department of the Interior or 
the Department of Agriculture, including on a contract basis.
    (b) Applicability.--Nothing in this section shall require the 
separation of any employee serving pursuant to an appointment that took 
effect, or an individual whose services under contract began, before 
the date of the enactment of this Act.
                                 <all>
```